Balancing the risks and benefits of erythropoietin-stimulating agents and iron therapy
- 1. Kidney Health Australia. Key chronic kidney disease (CKD) statistics in Australia. http://www.kidney.org.au/HealthProfessionals/CKDinAustralia/ tabid/622/Default.aspx (accessed May 2013).
- 2. Razavian M, Heeley EL, Perkovic V, et al. Cardiovascular risk management in chronic kidney disease in general practice (the AusHEART study). Nephrol Dial Transplant 2012; 27: 1396-1402.
- 3. Mercadal L, Metzger M, Casadevall, et al. Timing and determinants of erythropoietin deficiency in chronic kidney disease. Clin J Am Soc Nephrol 2012; 7: 35-42.
- 4. Goldsmith D. 2009: a requiem for rHuEPOs – but should we nail down the coffin in 2010? Clin J Am Soc Nephrol 2010; 5: 929-935.
- 5. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012; 4: 279-335.
- 6. MacGinley R, Walker R, Irving M. KHA-CARI Guidelines. Use of iron in chronic kidney disease patients [draft]. August 2012. http://www.cari.org.au/DIALYSIS_bht_published/DRAFT_Iron_18_March_2013.pdf (accessed Apr 2013).
- 7. McMahon L, MacGinley R. KHA-CARI Guidelines. Biochemical and haematological targets: haemoglobin levels in patients using erythropoiesis stimulating agents. October 2011. http://www.cari.org.au/DIALYSIS_bht_published/KHA_CARI_Anaemia_guidelines_November_%202011.pdf (accessed Apr 2013).
- 8. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
- 9. Pfeffer MA, Burdmann EA, Chen CY, et al; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
- 10. Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010; 153: 23-33.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.